Table 3.
Treatments before CNS metastasis.
| Number of Patients (n = 72) | Percent of all respondents | |
|---|---|---|
| Focal XRT | 33 | 46% |
| Topical Mustard/Carmustine | 25 | 35% |
| PUVA/UVB | 23 | 32% |
| TSEB | 17 | 24% |
| IFN | 15 | 21% |
| Combination Chemo: CMED/CEOP/COPP/MOPP/MCVP | 13 | 18% |
| MTX (PO or IV) | 12 | 17% |
| Single Agent Chemo: Doxorubicin/Gemcitabine/Cyclophosphamide/Vincristine/Chlorambucil | 12 | 17% |
| Steroids (Topical) | 11 | 15% |
| Bexarotene/Other Retinoid | 9 | 13% |
| Steroids (Systemic) | 8 | 11% |
| HDACi (Vorinostat/Romidepsin) | 2 | 3% |
| Bortezomib | 1 | 1% |
| IL2 | 1 | 1% |
| Zanolimumab | 1 | 1% |
| Arsenic Drop | 1 | 1% |
| Apheresis | 1 | 1% |